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Abstract Introduction: For optimal oncological care, it is recommended to discuss every pa-
tient with cancer in a multidisciplinary team meeting (MDTM). This is a time consuming and
expensive practice, leading to a growing demand to change the current workflow. We aimed to
investigate the number of patients discussed in MDTMs and to identify characteristics asso-
ciated with not being discussed.
Methods: Data of patients with a newly diagnosed solid malignant tumour in 2015 and 2016
were analysed through the nationwide population-based Netherlands Cancer Registry (NCR).
We clustered tumour types in groups that were frequently discussed within a tumour-specific
MDTM. Tumour types without information about MDTMs in the NCR were excluded.
Multivariable logistic regression analyses were used to analyse factors associated with not be-
ing discussed.
Results: Out of 105.305 patients with cancer, 91% were discussed in a MDTM, varying from
74% to 99% between the different tumour groups. Significantly less frequently discussed were
patients aged 75 years (odds ratio [OR]Z 0.7, 95% confidence interval [CI]Z 0.6e0.7), pa-
tients diagnosed with disease stage I (OR Z 0.5, 95% CI Z 0.5e0.6), IV (OR Z 0.4, 95%
CI Z 0.4e0.4) or unknown (OR Z 0.2, 95% CI Z 0.2e0.2) and patients who received no
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treatment (ORZ 0.3, 95% CIZ 0.3e0.3). Patients who received a multidisciplinary treatment
were more likely to be discussed in contrary to a monodisciplinary treatment (ORZ 4.6, 95%
CI Z 4.2e5.1).
Conclusion: In general, most patients with cancer were actually discussed in a MDTM,
although differences were observed between tumour groups. Factors associated with not being
discussed may, at least partially, reflect the absence of a multidisciplinary question. These re-
sults form a starting point for debate on a more durable and efficient new MDTM strategy.
ª 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Multidisciplinary teamwork is mandatory to provide
optimal oncological care for every patient with cancer in
a complex and changing oncological field [1e3]. This is
nowadays organised in multidisciplinary team meetings
(MDTMs), mostly weekly meetings of medical special-
ists of different health care disciplines [4e6], including a
surgeon, medical oncologist, radiation oncologist, radi-
ologist, pathologist, treating physician, specialised nurse
and an administrator [7].
After the appearance of the Calman-Hine report in
1995, which described principles about how to organise
and structure high-quality multidisciplinary care [8],
MDTMs were set out in accordance with these princi-
ples worldwide and, today, constitute the standard of
care [4, 9e11] although strong evidence supporting
survival benefit is lacking. A recent systematic review
analysed 27 articles about MDTMs (all tumour types
included). Of the 6 studies that assessed survival benefit,
only 2 were positive [12e14]. A third more recent article
published in 2017 shows that pre-treatment MDTM
discussion improved two-year relapse-free survival of
patients with sarcoma (65.4% versus 76.9%, p < 0.001
for a total of 9646 patients) [15].
Multidisciplinary teamwork is time consuming and
therefore expensive. A systematic review published in
2013 concluded that there is insufficient evidence to
determine whether multidisciplinary team (MDT)
working is actually cost-effective. Fifteen randomised
controlled trials about multidisciplinary teamwork were
analysed, of whom 4 were cancer MDTMs [16].
Performing a randomised controlled prospective trial,
comparing clinical and financial outcomes of patients
with cancer discussed or not discussed in MDTMs is no
longer feasible because MDTMs are completely inte-
grated in daily practice. Besides, evidence does show
that MDTMs improve staging, improve effective plan-
ning of diagnostics and therapy, enhance better
communication between involved departments and
improve decision-making and adherence to
guidelines [4,12,17e22].
Several national guidelines, such as in the
Netherlands (23), United Kingdom (10, 24), France
(25), United States of America (5) and Australia (26),
demand to discuss (nearly) all patients with cancer in a
MDTM. Owing to increasing incidence and prevalence
of cancer, centralisation of care, the rise of more
tumour-specific MDTMs (9) and increasing amount of
multidisciplinary treatment approaches, the number of
patients needed to be discussed in a MDTM is growing
in an unsustainable way [27,28].
A change in the organisation of MDTMs is therefore
needed. But to restructure oncologic MDT working, it is
essential to know more about current practice. Is every
patient actually discussed? For this purpose, we inves-
tigated whether or not 105.000 Dutch patients with
cancer were discussed in MDTMs, trying to identify the
factors that contribute to not being discussed. Our re-
sults will open up the debate about ways to restructure
MDTMs towards a more durable and efficient MDTM
strategy.
2. Materials and methods
Data of the nationwide population-based Netherlands
Cancer Registry (NCR) were used. This register in-
cludes data from an area of approximately 17 million
inhabitants, the total Dutch population. The NCR
uses the national automated pathological archive, to
include all newly diagnosed malignancies in the
Netherlands. Additional sources for notifications are
the national registry of hospital discharge and
radiotherapy institutions. Specially trained data
managers of the NCR routinely extract information
on diagnosis, tumour stage and treatment from the
medical records. Since 2015, for a selection of tumour
types, whether or not a patient is discussed in a
MDTM is also routinely recorded. Information on
vital status is obtained through annual linkage with
the Municipal Administrative Database, in which all
deceased and emigrated persons in the Netherlands
are registered.
We included patients newly diagnosed with an inva-
sive solid malignancy in 2015 and 2016. We formed eight
groups of patients according to tumour types, who are
regularly discussed within the same tumour-specific
MDTM, namely upper gastrointestinal (GI) cancer
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(oesophagus, cardiac, stomach and duodenal cancers),
hepato-pancreatic-biliary (HPB) cancer, colorectal can-
cer (CRC), gynaecological cancer (cervical, endometrial
and ovarian cancers), central nerve system (CNS) can-
cer, head and neck cancer (HNC), breast cancer and
prostate cancer. For patients with prostate cancer, the
necessary data were only available since October
2015 because of an expansion of the items that were
collected in the NCR since then, initiated by the ProZIB
initiative aimed at providing insight into the quality of
prostate cancer care in the Netherlands.
An extensive item set per patient is collected by the
NCR data managers. The items within this set differ per
tumour type, based on national agreements. Unfortu-
nately, for lung, renal and bladder cancer, melanoma
and sarcoma, no data on MDTM discussions were
recorded, and therefore, these tumour types were
excluded.
Patients with haematologic cancer were excluded
because of the different organisation of care in the
Netherlands. Furthermore, patients with nonmelanoma
skin cancers (squamous cell carcinoma and basal cell
carcinoma) were excluded because of the lack of multi-
disciplinary discussion in these mostly only surgically
treated patients.
The percentage of patients being discussed in
MDTMs in total and per tumour group was investigated
using univariable analyses followed by a multivariable
logistic regression on the chance of being discussed in a
MDTM. In these multivariable analyses, we adjusted for
five different factors that might contribute to being
discussed in a MDTM: age at diagnosis (four categories:
44, 45e59, 60e74 or 75 years), disease stage (by
tumour-node-metastasis (TNM) or International
Federation of Gynaecology and Obstetrics (FIGO) for
gynaecological cancerdand not applicable for CNS
cancer), treatment (none, monodisciplinary or multi-
disciplinary), number of comorbidities (0, 1, 2e4 or >5)
and geographical location of hospital of diagnosis
(divided into four regions based on the provinces of the
Netherlands). We excluded short-term survival from the
multivariable analyses because of possible multi-
collinearity with receiving no treatment. Comorbidity
was not routinely registered for all patients and not
included in the analyses if lacking in more than 70% of
patients. This applied to HNC, CNS cancer, and breast
cancer.
As mentioned, data about MDTM discussion were
not recorded for some tumour groups. For an estima-
tion on the percentage of discussion of all patients with a
solid malignant tumour (excluding nonmelanoma skin
cancer, including the tumour groups with not recorded
data), we performed a sensitivity analysis using multiple
imputation. Therefore, the missing data on MDTM
discussions of all groups except prostate cancer were
imputated (10 times per patient) based on the data of the
groups for which MDTM discussions were registered
within the NCR with a logistic regression model with the
following factors: age, disease stage, comorbidity,
treatment (none, monodisciplinary or multidisciplinary),
region (based on the provinces in the Netherlands), year
of diagnosis and 90-day mortality. A separate multiple
imputation analysis was made for patients with prostate
cancer based on the data of these patients with known
MDTM values (October 2015eDecember 2016) because
we missed data from only JanuaryeSeptember 2015 for
this group.
3. Results
We analysed 105.319 patients with a new diagnosis of an
invasive solid malignant tumour in the Netherlands in
2015 and 2016. Of them, 91% were actually discussed in
a MDTM (Table 1). The highest MDTM rates were
found for CRC (93%), HNC (95%), CNS cancer
(91%) and breast cancer (99%). Less frequently dis-
cussed were HPB (74%), prostate (80%), upper
GI (84%) and gynaecological cancer (89%). Different
factors were univariably related to being less frequently
discussed: age 75 years (of this age group, 84% was
discussed), disease stages I, IV and unknown (of these
disease stage groups, 91%, 83% and 73% of patients,
respectively, were discussed), receiving no treatment or
only systemic treatment (64% and 86% of patients in
these treatment groups were discussed) and deceased
within 90 days of diagnosis (of these, only 63% were
discussed). Sensitivity analysis based on 181.241
patients with an invasive solid malignant tumour
(including tumour types with missing data in the NCR,
excluding nonmelanoma skin cancer), diagnosed in 2015
and 2016, shows a discussion rate of 88%
(Supplementary table A).
Table 2 presents the multivariable logistic regression
analysis on the chance of being discussed in a MDTM.
The total group analysis shows a less frequent discussion
for patients with age 75 years (odds ratio [OR] Z 0.7,
95% confidence interval [CI] Z 0.6e0.7) or without a
treatment (ORZ 0.3, 95% CIZ 0.3e0.3). Patients with
a monodisciplinary treatment plan were less likely to be
discussed than those with a multidisciplinary treatment
plan (OR Z 4.6, 95% CI Z 4.2e5.1). The chance to be
discussed was slightly lower in region D than in A, B or
C. The number of comorbidities did not make a differ-
ence. Patients were more likely to be discussed with
disease stages II and III, compared with I, IV or
unknown.
Differences were noted per tumour group. Older pa-
tients (75 years) were significantly less often discussed
within tumour groups CRC, HNC, HPB, gynaeco-
logical, breast and prostate cancers. In all different
tumour groups, we found significant associations with
being less frequently discussed in disease stages I, IV
and/or unknown. The number of comorbidities was
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Table 1
Univariable analyses of the number and percentage of patients discussed in MDTMs in 2015 and 2016 according to the nationwide population-
based Netherlands Cancer registry data.
Tumour groups Upper GI
cancers
HPB
cancers
Colorectal
carcinoma
Gynaecological
cancers
CNS
cancers
N (%) % pts
discussed in
MDTMs
N (%) % pts
discussed in
MDTMs
N (%) % pts
dis cussed in
MDTMs
N (%) % pts
discussed in
MDTMs
N (%) % pts
discussed in
MDTMs
Number of
patients
N (% of total) 7704 (7) 84 7397 (7) 74 30831 (29) 93 7671 (7) 89 2000 (2) 91
Gender
Male 5419 (70) 85 4048 (55) 76 17603 (57) 94 0 (0) NA 1211 (61) 92
Female 2285 (30) 82 3349 (45) 71 13228 (43) 93 7671 (100) 89 789 (39) 90
Age (years)
44 136 (2) 89 110 (1) 84 567 (2) 98 775 (10) 96 434 (22) 88
45e59 1214 (16) 88 1078 (15) 84 4262 (14) 96 1712 (22) 91 587 (29) 93
60e74 3709 (48) 88 3513 (47) 81 16253 (53) 95 3189 (42) 90 796 (40) 92
75 2645 (34) 77 2696 (36) 60 9738 (32) 89 1995 (26) 82 183 (9) 93
Stage (TNM or
FIGOa)
I 1072 (14) 80 691 (9) 76 7860 (26) 92 3968 (52) 87 NA NA
II 1097 (14) 95 1585 (21) 90 7270 (24) 97 698 (9) 95 NA NA
III 2040 (26) 97 1159 (16) 86 8897 (29) 98 1646 (21) 93 NA NA
IV 3001 (39) 79 3546 (48) 64 6064 (20) 86 1205 (16) 90 NA NA
X 494 (6) 47 416 (6) 52 729 (2) 61 154 (2) 55 NA NA
Primary
treatment
No 2004 (26) 63 4028 (54) 60 2394 (8) 64 656 (9) 63 52 (3) 63
Yes 5700 (74) 92 3369 (46) 90 28426 (92) 96 7015 (91) 91 1948 (97) 92
Type of
treatment
None 2004 (26) 63 4028 (54) 60 2394 (8) 64 656 (9) 63 52 (3) 63
Surgery (Sur) 763 (10) 76 1245 (17) 96 16476 (53) 95 2893 (38) 86 466 (23) 87
Radiotherapy (Rtx) 965 (13) 92 134 (2) 81 529 (2) 95 154 (2) 95 14 (1) 86
Systemic therapy (Syst) 909 (12) 83 1306 (18) 82 1700 (6) 86 591 (8) 90 3 (<0.5) NA
Sur þ Rtx 11 (<0.5) NA 16 (<0.5) NA 1464 (5) 100 1129 (15) 91 408 (20) 91
Sur þ Syst 556 (7) 99 525 (7) 99 5144 (17) 99 1636 (21) 99 109 (5) 95
Rtx þ Syst 1068 (14) 96 98 (1) 93 692 (2) 98 323 (4) 99 5 (<0.5) NA
Sur þ Rtx þ Syst 1428 (19) 99 45 (1) 100 2421 (8) 100 289 (4) 99 943 (47) 95
Number of
comorbiditiesb
0 1715 (22) 87 1098 (15) 76 5412 (18) 95 2583 (34) 92 117 (6) NA
1 2010 (26) 86 1604 (22) 75 5765 (19) 94 2146 (28) 89 88 (4) NA
2e4 3210 (42) 83 2370 (32) 69 7203 (23) 93 2272 (30) 85 58 (3) NA
>5 315 (4) 78 151 (2) 68 592 (2) 90 118 (2) 81 3 (<0.5) NA
Unknown 454 (6) 79 2174 (29) 77 11848 (38) 93 552 (7) 85 1734 (87) NA
Regionc
A 995 (13) 84 856 (12) 67 3641 (12) 93 839 (11) 87 232 (12) 92
B 1608 (21) 85 1583 (21) 73 6916 (22) 94 1678 (22) 86 438 (22) 88
C 1966 (26) 86 1741 (24) 73 7895 (26) 94 1978 (26) 89 433 (22) 96
D 3135 (41) 83 3217 (43) 76 12368 (40) 93 3176 (41) 91 897 (45) 90
Short-term
survival (days)d
<30 618 (8) 43 1189 (16) 43 897 (3) 44 231 (3) 48 91 (5) 77
30e90 1014 (13) 76 1692 (23) 63 1216 (4) 78 298 (4) 80 204 (10) 91
>90 6072 (79) 90 4516 (61) 86 28707 (93) 96 7142 (93) 90 1705 (85) 92
Tumour groups Head and neck cancerse Breast cancer Prostate cancerf Total
N (%) % pts discussed
in
MDTMs
N (%) % pts discussed
in MDTMs
N (%) % pts discussed
in MDTMsg
N (%) % pts discussed
in
MDTMs
Number of patients
N (% of total) 5398 (5) 95 31313 (30) 99 13005 (12) 80 105319 (100) 91
Gender
Male 3575 (66) 95 229 (1) 99 13004 (100) 80 45080 (43) 87
Female 1822 (34) 94 31083 (99) 99 0 (0) NA 60225 (57) 94
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more difficult to investigate because it was unavailable
in HNC, breast and CNS cancers. For CRC, the pres-
ence of >5 comorbidities was related to more frequently
being discussed. Geographical region appeared to have
impact on being discussed in a MDTM for all tumour
groups except breast cancer.
4. Discussion
In our large cohort of 105.000 patients with cancer, 91%
was discussed in a MDTM. This is in accordance with
the Dutch SONCOS (national multidisciplinary plat-
form to provide guidelines for oncological care)
Table 1 (continued )
Tumour groups Head and neck cancerse Breast cancer Prostate cancerf Total
N (%) % pts discussed
in
MDTMs
N (%) % pts discussed
in MDTMs
N (%) % pts discussed
in MDTMsg
N (%) % pts discussed
in
MDTMs
Age (years)
44 148 (3) 96 2937 (9) 99 7 (0) 86 5114 (5) 97
45e59 1266 (23) 97 10388 (33) 99 1268 (10) 83 21775 (21) 95
60e74 2755 (51) 96 12243 (39) 99 8135 (63) 83 50593 (48) 92
75 1228 (23) 91 5744 (18) 97 3594 (28) 74 27823 (26) 84
Stage (TNM)
I 1597 (30) 88 14906 (48) 100 5000 (38) 72 3912 (4) 91
II 804 (15) 98 11383 (36) 99 2534 (19) 85 35094 (33) 96
III 756 (14) 98 3199 (10) 99 2189 (17) 88 25371 (24) 96
IV 2186 (41) 98 1789 (6) 88 3251 (25) 85 19886 (19) 83
X 54 (1) 61 35 (<0.5) 94 30 (<0.5) 23 21042 (20) 73
Primary treatment
No 481 (9) 87 484 (2) 77 3616 (28) 65 13715 (13) 64
Yes 4916 (91) 96 30828 (98) 99 9388 (72) 86 91590 (87) 95
Type of treatment
None 481 (9) 87 484 (2) 77 3616 (28) 65 13715 (13) 64
Surgery (Sur) 1554 (29) 88 2518 (8) 100 2858 (22) 84 28773 (27) 92
Radiotherapy (Rtx) 1519 (28) 99 57 (0) 96 1444 (11) 85 4816 (5) 92
Systemic therapy (Syst) 29 (1) 93 2689 (9) 93 2445 (19) 80 9672 (9) 86
Sur þ Rtx 792 (15) 99 6358 (20) 100 105 (1) 97 10283 (10) 98
Sur þ Syst 6 (<0.5) NA 4826 (15) 100 210 (2) 93 13012 (12) 99
Rtx þ Syst 820 (15) 100 304 (1) 88 1848 (14) 93 5158 (5) 95
Sur þ Rtx þ Syst 196 (4) 100 14076 (45) 100 478 (4) 97 19876 (19) >99.5
Number of
comorbiditiesb
0 99 (2) NA 1950 (6) NA 1987 (15) 80 14961 (14) 91
1 190 (4) NA 1605 (5) NA 2036 (16) 80 15444 (15) 89
2e4 292 (5) NA 1404 (4) NA 2242 (17) 78 19051 (18) 86
>5 20 (<0.5) NA 100 (0) NA 161 (1) 76 1460 (1) 83
Unknown 4796 (89) NA 26253 (84) NA 6578 (51) 81 54389 (52) 94
Regionc
A 730 (14) 96 3591 (11) 98 1757 (14) 90 12641 (12) 91
B 1149 (21) 96 6922 (22) 99 2894 (22) 85 23188 (22) 92
C 1297 (24) 97 7483 (24) 99 3137 (24) 79 25930 (25) 92
D 2220 (41) 93 13315 (43) 99 5216 (40) 75 43544 (41) 90
Short-term survival
(days)d
<30 87 (2) 78 165 (1) 57 70 (1) 31 3348 (3) 46
30e90 223 (4) 94 225 (1) 84 100 (1) 66 4972 (5) 74
>90 5087 (94) 95 30922 (99) 99 12834 (99) 81 96985 (92) 93
MDTM Z multidisciplinary team meeting; N Z number of patients; stage X Z unknown; pts Z patients; TNM Z tumour-node-metastasis;
FIGO Z International Federation of Gynaecology and Obstetrics.
upper GI cancers Z oesophagus, cardiac, stomach and duodenal cancers; HPB cancers Z hepato-pancreatic-biliary cancers; gynaecological
cancers Z cervical, endometrial and ovarian cancers; CNS cancers Z central nervous system cancers.
a FIGO staging for gynaecological cancers.
b When <0.5% of patients received a certain type of treatment or when comorbidities were not registered for >70% of patients, analyses ac-
cording to percentages of patients discussed in MDTMs were deleted.
c Region Z regions of hospital of diagnosis divided into four based on the provinces in the Netherlands. The regions were coded.
d Short-term survival Z time between the date of diagnosis and the date of death.
e Head and neck cancers only include patients referred to academic centres (missing Z 2%).
f Prostate cancers: data available since October 2015.
g Being discussed with MDTM report in the medical record.
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guidelines, which state that at least 90% of patients
should be discussed [23]. Many international guidelines
state that (nearly) all patients should be discussed in a
MDTM without quantification [5,10,23e26]. The
threshold of 90% was reached for CRC, HNC, CNS and
breast cancers but was not reached for HPB, prostate,
upper GI and gynaecological cancers. Based on our
dataset, we cannot explain the differences between the
tumour groups. It might be clear that this 90% is an
arbitrarily chosen threshold, with a lack of supportive
evidence.
In a recent Belgian study of 205.062 patients, the
number of patients being discussed in MDTMs
increased over time, from 36e77% in 2004 to 69e94% in
2011. As in our study, patients aged 80 years or with
disease stages I, IV and/or unknown were less likely to
be discussed for all seven included tumour types [29]. In
addition, our data were up to 2016 and we showed
that patients with multidisciplinary treatment were
significantly more likely to be discussed than those with
monodisciplinary treatment.
Taken together, the need to formulate a multidisci-
plinary treatment plan seems the most important
determinant for being discussed in a MDTM. Older
patients might be unable or unwilling to receive
(multidisciplinary) treatment because of reduced phys-
ical condition, and we hypothesise that patients with
disease stages I and IV are more likely to receive a
monodisciplinary treatment, such as local surgical
resection (stage I) or systemic medical treatment ap-
proaches or no treatment (stage IV). For patients with
disease stage ‘unknown’, we assume that the inability to
perform all necessary diagnostics to complete staging is
associated with getting no treatment and/or impaired
performance status. Our data support this hypothesis;
for instance, patients with upper GI cancer were less
frequently discussed (84%). This lower discussion rate is
explained by disease stage I (80%), IV (79%) and ‘un-
known’ (47%). Patients with stages II and III have
remarkably higher discussion rates (95% and 97%,
respectively). We see similar patterns for the other
tumour types with lower discussion rates. However,
limited by the retrospective design of the current anal-
ysis, one might hypothesise that patients were not
receiving multidisciplinary treatments as a result of not
being discussed.
We might have expected an impact of the number of
comorbidities on MDTM discussion rates, but in fact,
there was no significant association, with the exception
of patients with CRC with more than 5 comorbidities.
For HNC, CNS and breast cancers, no data on the
number of comorbidities was available. Because the
number of comorbidities did not make a difference in
discussion rates in the remaining tumour groups, this
does not seem to be crucial.
We found differences between the tumour groups
based on the geographical region even in a small
country such as the Netherlands, with a lowered dis-
cussion rate in region D, compared with regions A, B
and C. Within the collected data, no explanation for
this difference can be found. There are no differences
in the health care system and its accessibility within the
Netherlands. However, regional differences are not
completely unusual in oncological care. A study in
2016 showed regional differences in liver surgery for
patients with colorectal cancer [30], and another article
reported that the hospital of diagnosis influences the
probability to get gastric surgery in patients with
gastric cancer [31].
A limitation of this study is the exclusion of patients
with melanoma, sarcoma, lung, renal, and bladder
cancers due to lack of information about MDTMs in the
NCR, accounting for 42% of the total cancer incidence.
Nevertheless, more than 105.000 patients, with a large
variety of tumour types, were analysed, and the general
conclusions may be extrapolated to all tumour types in
the Netherlands. This hypothesis is reinforced by the
sensitivity analysis that shows a discussion percentage of
88% for all patients, when missing data was imputated.
Can we exclude patients without a multidisciplinary
question from MDTMs, in an era where MDTMs are
under pressure because of high costs and confiscation of
lots of time? In a retrospective analysis of a breast
cancer MDTM, 31% of the patients who were consid-
ered ‘fit’ after geriatric assessment did not receive the
appropriate adjuvant treatment, influenced by high age
and comorbidities as monitored by the MDT mem-
bers [32]. A ‘simple’ factor such as age is thus not able to
distinguish the need for MDT discussion. Distinguishing
based on the disease stage alone is not possible either. A
retrospective analysis of 1600 operated patients with
squamous cell carcinomas of the oral cavity showed
improved survival rates among patients who were dis-
cussed in MDTMs, compared with patients not being
discussed (for stage I, a 5-year overall survival rate was
82%e92% [pZ 0.023], and for stage IV, this was 45%e
50% [pZ 0.0194]) [33]. Should patients then be excluded
from MDT discussion based on individual characteris-
tics? This gives a chance of incorrectly excluding patients
to advanced multidisciplinary treatment options, such
as, for instance, curative treatment approaches of liver
surgery in patients in stage IV colorectal cancer with
liver metastasis [34].
5. Future directions
As mentioned, restructuring the workflow around
MDTMs seems inevitable in a changing oncological
field. Based on our results, it is not easy to exclude one
specific group from MDT discussion. Further research
should focus on patients who received a mono-
disciplinary treatment plan to make detailed compari-
sons of being discussed in MDTMs or not and receiving
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Table 2
Multivariable logistic regression analyses of percentage of patients discussed in multidisciplinary team meetings in 2015 þ 2016.
Tumour groups Upper GI cancers HPB cancers Colorectal carcinoma Gynaecological cancers CNS cancers
OR CI OR CI OR CI OR CI OR CI
Tumour groups
Upper GI cancers NA NA NA NA NA NA NA NA NA NA
HPB cancers NA NA NA NA NA NA NA NA NA NA
Colorectal carcinoma NA NA NA NA NA NA NA NA NA NA
Gynaecological cancers NA NA NA NA NA NA NA NA NA NA
CNS cancers NA NA NA NA NA NA NA NA NA NA
Head and neck cancers NA NA NA NA NA NA NA NA NA NA
Breast cancer NA NA NA NA NA NA NA NA NA NA
Prostate cancer NA NA NA NA NA NA NA NA NA NA
Age (years)
44 1.2 (0.6e2.1) 0.9 (0.5e1.5) 1.7 (1.0e3.0) 3.2 (2.2e4.8) 0.7 (0.5e1.1)
45e59 1.0 (0.7e1.3) 0.9 (0.8e1.1) 1.2 (1.0e1.4) 1.2 (1.0e1.4) 1.0 (0.7e1.6)
60e74 REF REF REF REF REF
75 1.0 (0.9e1.2) 0.5 (0.4e0.5) 0.7 (0.7e0.8) 0.8 (0.6e0.9) 1.5 (0.8e2.9)
Stage (TNM or
FIGOa)
I 0.3 (0.2e0.4) 0.5 (0.4e0.7) 0.3 (0.3e0.4) 0.4 (0.2e0.6) NA NA
II REF REF REF REF NA NA
III 1.4 (0.9e2.0) 1.0 (0.8e1.3) 0.8 (0.7e1.1) 1.3 (0.8e2.0) NA NA
IV 0.4 (0.3e0.6) 0.3 (0.3e0.4) 0.2 (0.2e0.3) 1.2 (0.8e1.8) NA NA
X 0.1 (0.1e0.2) 0.3 (0.2e0.4) 0.1 (0.1e0.2) 0.3 (0.2e0.5) NA NA
Type of treatmentb
None 0.4 (0.3e0.4) 0.3 (0.3e0.4) 0.2 (0.2e0.2) 0.2 (0.1e0.2) 0.3 (0.1e0.5)
Monodisciplinary REF REF REF REF REF
Multidisciplinary 6.1 (4.5e8.1) 3.7 (2.2e6.5) 5.0 (4.0e6.3) 2.6 (2.1e3.2) 2.3 (1.6e3.2)
Number of
comorbiditiesc
0 REF REF REF REF REF
1 1.1 (0.9e1.3) 1.1 (0.9e1.3) 1.1 (1.0e1.4) 0.9 (0.7e1.1) NA NA
2e4 1.2 (1.0e1.4) 1.0 (0.8e1.2) 1.2 (1.0e1.4) 0.8 (0.7e1.0) NA NA
>5 1.2 (0.9e1.7) 1.1 (0.7e1.7) 1.4 (1.0e2.0) 0.9 (0.5e1.5) NA NA
Unknown 0.8 (0.6e1.0) 1.1 (0.9e1.4) 1.0 (0.9e1.2) 0.6 (0.5e0.9) NA NA
Regiond
A 1.0 (0.8e1.2) 0.7 (0.6e0.8) 1.1 (1.0e1.3) 0.7 (0.6e1.0) 1.4 (0.8e2.5)
B 1.1 (0.9e1.3) 0.8 (0.7e1.0) 1.1 (1.0e1.2) 0.6 (0.5e0.8) 0.7 (0.5e1.0)
C 1.3 (1.1e1.5) 0.9 (0.8e1.1) 1.3 (1.1e1.5) 0.8 (0.7e1.0) 2.5 (1.4e4.2)
D REF REF REF REF REF
Tumour groups Head and neck cancerse Breast cancer Prostate cancerf Total
OR CI OR CI OR CI OR CI
Tumour groups
Upper GI cancers NA NA NA NA NA NA 0.6 (0.5e0.6)
HPB cancers NA NA NA NA NA NA 0.5 (0.4e0.5)
Colorectal carcinoma NA NA NA NA NA NA REF REF
Gynaecological cancers NA NA NA NA NA NA 0.5 (0.4e0.5)
CNS cancers NA NA NA NA NA NA 0.8 (0.7e1.0)
Head and neck cancers NA NA NA NA NA NA 1.3 (1.1e1.5)
Breast cancer NA NA NA NA NA NA 2.3 (2.0e2.6)
Prostate cancer NA NA NA NA NA NA 0.4 (0.4e0.4)
Age (years)
44 1.1 (0.4e2.7) 1.5 (0.8e2.5) 1.2 (0.1e10.8) 1.4 (1.2e1.7)
45e59 1.3 (0.9e1.9) 1.4 (1.0e2.0) 1.3 (1.0e1.3) 1.1 (1.0e1.2)
60e74 REF REF REF REF
75 0.6 (0.5e0.8) 0.7 (0.6e1.0) 0.6 (0.5e0.6) 0.7 (0.6e0.7)
Stage (TNM)
I 0.2 (0.1e0.3) 1.8 (1.2e2.7) 0.7 (0.6e0.8) 0.5 (0.5e0.6)
II REF REF REF REF
III 1.2 (0.6e2.5) 0.6 (0.4e1.0) 1.1 (0.9e1.3) 1.0 (0.9e1.1)
IV 1.3 (0.8e2.4) 0.1 (0.1e0.2) 1.0 (0.9e1.2) 0.4 (0.4e0.4)
X 0.1 (<0.05e0.1) 0.5 (0.1e2.1) 0.1 (<0.05e0.2) 0.2 (0.2e0.2)
Type of treatmentb
None 0.2 (0.1e0.3) 0.2 (0.1e0.2) 0.5 (0.4e0.6) 0.3 (0.3e0.3)
(continued on next page)
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the expected treatment based on clinical guidelines or
not.
We suggest subdividing patients into three different
categories: (1) low-volume high-complex cases, who
should be discussed by regional or national expert
teams, (2) high-volume low-complex cases with a good
performance status, to discuss by local panels of only 2
or 3 medical specialists and (3) the remaining patients
should be discussed in regular tumour-specific MDTMs,
with possibility to use expert consultation. A further
restructuring method for selected tumour types would
be a MDTM exclusively for patients with metastatic
disease to explore additional local (curative) treatment
options for these patients. This is to provide optimal
care for every patient, regardless of the hospital of first
referral. These restructuring methods are efficient and
prevent patients from being discussed several times at
different places.
6. Conclusion
Of more than 105.000 patients with a solid invasive
malignant tumour, diagnosed in 2015 or 2016, a high
number of patients (91%) were discussed in a MDTM.
Differences between different tumour groups were
found based on characteristics such as high age, disease
stage and the need of a multidisciplinary treatment plan.
These results form the starting point for debate on
restructuring MDTMs in such a way that high-quality
care and speed of care are maintained and time efforts
and costs are reduced, while increasing number of pa-
tients with cancer need to be discussed multidisciplinary.
Conflict of interest statement
All authors have no disclaimers of conflict of interest.
There were no funding sources for this research.
Appendix A. Supplementary data
Supplementary data to this article can be found online
at https://doi.org/10.1016/j.ejca.2019.08.007.
References
[1] Wright FC, Lookhong N, Urbach D, Davis D, McLeod RS,
Gagliardi AR. Multidisciplinary cancer conferences: identifying
opportunities to promote implementation. Ann Surg Oncol 2009;
16(10):2731e7. https://doi.org/10.1245/s10434-009-0639-6.
[2] Gouveia J, Coleman MP, Haward R, Zanetti R, Hakama M,
Borras JM, et al. Improving cancer control in the European
Union: conclusions from the Lisbon round-table under the Por-
tuguese EU Presidency, 2007. Eur J Cancer 2008;44(10):1457e62.
https://doi.org/10.1016/j.ejca.2008.02.006.
[3] Ouwens M, Hulscher M, Hermens R, Faber M, Marres H,
Wollersheim H, et al. Implementation of integrated care for pa-
tients with cancer: a systematic review of interventions and effects.
Int J Qual Health Care : Journal of the International Society
for Quality in Health Care 2009;21(2):137e44. https:
//doi.org/10.1093/intqhc/mzn061.
[4] El Saghir NS, Keating NL, Carlson RW, Khoury KE,
Fallowfield L. Tumor boards: optimizing the structure and
improving efficiency of multidisciplinary management of patients
Table 2 (continued )
Tumour groups Head and neck cancerse Breast cancer Prostate cancerf Total
OR CI OR CI OR CI OR CI
Monodisciplinary REF REF REF REF
Multidisciplinary 4.6 (2.3e9.0) 7.0 (5.0e9.8) 3.6 (3.0e4.3) 4.6 (4.2e5.1)
Number of comorbiditiesc
0 NA NA NA NA REF REF
1 NA NA NA NA 1.0 (0.9e1.2) 1.0 (0.9e1.1)
2e4 NA NA NA NA 0.9 (0.8e1.1) 1.0 (0.9e1.1)
>5 NA NA NA NA 0.9 (0.6e1.4) 1.1 (0.9e1.3)
Unknown NA NA NA NA 1.1 (1.0e1.3) 1.0 (1.0e1.1)
Regiond
A 2.1 (1.4e3.2) 0.8 (0.5e1.1) 3.4 (2.9e4.1) 1.3 (1.2e1.4)
B 1.9 (1.4e2.8) 1.2 (0.9e1.6) 2.0 (1.8e2.3) 1.2 (1.1e1.2)
C 2.1 (1.5e3.0) 1.3 (1.0e1.8) 1.4 (1.2e1.6) 1.2 (1.6e1.3)
D REF REF REF REF
OR Z odds ratio; CI Z confidence interval; stage X Z unknown; TNM Z tumour-node-metastasis.
Upper GI cancers Z oesophagus, cardiac, stomach and duodenal cancers; HPB cancers Z hepato-pancreatic-biliary cancers; gynaecological
cancers Z cervical, endometrial and ovarian cancers; CNS cancers Z central nervous system cancers.
Significant results are marked in bold with p-values < 0.05.
a FIGO staging for gynaecological cancers.
b Monodisciplinary treatment contains surgery, radiotherapy or systemic therapy. Multidisciplinary treatment contains a combination of two
or three of these treatment modalities.
c When comorbidities were not registered for >70% of patients, analyses according to percentages of patients discussed in MDTMs were deleted
(except for the total analysis).
d Region Z regions of hospital of diagnosis divided into four based on the provinces in the Netherlands. The regions were coded.
e Head and neck cancers only include patients referred to academic centres (missing Z 2%).
f Prostate cancers; data available since October 2015.
J.E.W. Walraven et al. / European Journal of Cancer 121 (2019) 85e9392
with cancer worldwide. In: American society of clinical oncology
educational book. American society of clinical oncology.
Meeting; 2014. e461e6. https://doi.org/10.14694/EdBook_AM.
2014.34.e461.
[5] American college of surgeons C, IL. Commission on cancer.
Cancer program standards 2012, ensuring patient-centered care.
2012.
[6] Fennell ML, Das IP, Clauser S, Petrelli N, Salner A. The orga-
nization of multidisciplinary care teams: modeling internal and
external influences on cancer care quality. J Natl Cancer Inst
Monogr 2010;2010(40):72e80. https://doi.org/10.1093/jncimono-
graphs/lgq010.
[7] Ottevanger N, Hilbink M, Weenk M, Hermens R. Oncologic
multidisciplinary team meetings: evaluation of quality criteria. J
Eval Clin Pract 2013;19(6):1035e43. https://doi.org/10.1111/jep.
12022.
[8] Health Do. A policy framework for commissioning cancer ser-
vices: a report by the expert advisory group on cancer to the chief
medical officers of england and wales. BMJ 1995. https:
//doi.org/10.1136/bmj.310.6992.1425.
[9] Borras JM, Albreht T, Audisio R, Briers E, Casali P, Esperou H,
et al. Policy statement on multidisciplinary cancer care. Eur J
Cancer 2014;50(3):475e80. https://doi.org/10.1016/j.ejca.2013.11.
012.
[10] Griffith C, Turner J. United Kingdom national health service,
cancer services collaborative "improvement partnership", redesign
of cancer services: a national approach. Eur J Surg Oncol : the
journal of the European Society of Surgical Oncology and the
British Association of Surgical Oncology 2004;30(Suppl 1):1e86.
https://doi.org/10.1016/j.ejso.2004.07.010.
[11] Juan A, Berlanga P, Bisogno G, Michon J, Valteau-Couanet D,
Kearns P, et al. Paediatric tumour boards in Europe: current
situation and results of an international survey in expo-r-net.
Pediatr Blood Cancer 2016;63:S152.
[12] Pillay B, Wootten AC, Crowe H, Corcoran N, Tran B, Bowden P,
et al. The impact of multidisciplinary team meetings on patient
assessment, management and outcomes in oncology settings: a
systematic review of the literature. Cancer Treat Rev 2016;42:
56e72. https://doi.org/10.1016/j.ctrv.2015.11.007.
[13] Bydder S, Nowak A, Marion K, Phillips M, Atun R. The impact
of case discussion at a multidisciplinary team meeting on the
treatment and survival of patients with inoperable non-small cell
lung cancer. Intern Med J 2009;39(12):838e41. https:
//doi.org/10.1111/j.1445-5994.2009.02019.x.
[14] MacDermid E, Hooton G, MacDonald M, McKay G, Grose D,
Mohammed N, et al. Improving patient survival with the colo-
rectal cancer multi-disciplinary team. Colorectal Dis : The Official
Journal of the Association of Coloproctology of Great Britain
and Ireland 2009;11(3):291e5. https://doi.org/10.1111/j.1463-
1318.2008.01580.x.
[15] Blay JY, Soibinet P, Penel N, Bompas E, Duffaud F, Stoeckle E,
et al. Improved survival using specialized multidisciplinary board
in sarcoma patients. Ann Oncol : Official Journal of the European
Society for Medical Oncology 2017;28(11):2852e9. https:
//doi.org/10.1093/annonc/mdx484.
[16] Ke KM, Blazeby JM, Strong S, Carroll FE, Ness AR,
Hollingworth W. Are multidisciplinary teams in secondary care
cost-effective? A systematic review of the literature. Cost Eff
Resour Allocation : C/E. 2013;11(1):7. https://doi.org/10.
1186/1478-7547-11-7.
[17] Taplin SH, Weaver S, Salas E, Chollette V, Edwards HM,
Bruinooge SS, et al. Reviewing cancer care team effectiveness.
Journal of Oncology Practice 2015;11(3):239e46. https:
//doi.org/10.1200/jop.2014.003350.
[18] Abdulrahman Jr GO. The effect of multidisciplinary team care on
cancer management. The Pan African medical journal 2011;9:20.
[19] Brar SS, Hong NL, Wright FC. Multidisciplinary cancer care:
does it improve outcomes? J Surg Oncol 2014;110(5):494e9.
https://doi.org/10.1002/jso.23700.
[20] Devitt B, Philip J, McLachlan SA. Team dynamics, decision
making, and attitudes toward multidisciplinary cancer meetings:
health professionals’ perspectives. Journal of oncology practice
2010;6(6):e17e20.
[21] Fleissig A, Jenkins V, Catt S, Fallowfield L. Multidisciplinary
teams in cancer care: are they effective in the UK? The Lancet.
Oncology 2006;7(11):935e43. https://doi.org/10.1016/s1470-
2045(06)70940-8.
[22] Prades J, Remue E, Van Hoof E, Borras J. Multidisciplinary
teams in cancer care: a systematic review of the evidence. Eur J
Cancer 2013;49:S327.
[23] SONCOS normeringrapport 6; Multidisciplinaire oncologische
zorg in Nederland. 2018.
[24] Dew K, Stubbe M, Signal L, Staimand J, Dennett E, Koea J, et al.
Cancer care decision making in multidisciplinary meetings. Qual
Health Res 2015;25(3):397e407. https://doi.org/10.1177/
1049732314553010.
[25] Cannell E. The French cancer plan: an update. Lancet Oncol
2005;6(10):738.
[26] Victorian cancer plan 2016-2020; Improving cancer outcomes for
all Victorians: www.healthvic.gov.au/cancer.
[27] Registry NpbNC. https://www.cijfersoverkanker.nl/.
[28] Kowalski C, Graeven U, von Kalle C, Lang H, Beckmann MW,
Blohmer JU, et al. Shifting cancer care towards Multi-
disciplinarity: the cancer center certification program of the
German cancer society. BMC Canc 2017;17(1):850. https:
//doi.org/10.1186/s12885-017-3824-1.
[29] Dubois C, De Schutter H, Leroy R, Stordeur S, De Gendt C,
Schillemans V, et al. Multidisciplinary work in oncology: popu-
lation-based analysis for seven invasive tumours. Eur J Cancer
Care 2018;27(2). https://doi.org/10.1111/ecc.12822. e12822.
[30] t Lam-Boer J, van der Stok EP, Huiskens J, Verhoeven RH,
PuntCJ, ElferinkMA, et al. Regional and inter-hospital differences
in the utilisation of liver surgery for patients with synchronous
colorectal liver metastases in The Netherlands. Eur J Cancer 2017;
71:109e16. https://doi.org/10.1016/j.ejca.2016.10.026.
[31] van Putten M, Verhoeven RH, van Sandick JW, Plukker JT,
Lemmens VE, Wijnhoven BP, et al. Hospital of diagnosis and
probability of having surgical treatment for resectable gastric
cancer. Br J Surg 2016;103(3):233e41. https://doi.org/10.1002/bjs.
10054.
[32] Barthelemy P, Heitz D, Mathelin C, Polesi H, Asmane I,
Litique V, et al. Adjuvant chemotherapy in elderly patients with
early breast cancer. Impact of age and comprehensive geriatric
assessment on tumor board proposals. Crit Rev Oncol-Hematol
2011;79(2):196e204.
[33] Liao CT, Kang CJ, Lee LY, Hsueh C, Lin CY, Fan KH, et al.
Association between multidisciplinary team care approach and
survival rates in patients with oral cavity squamous cell carci-
noma. Head Neck 2016;38(Suppl 1):E1544e53. https:
//doi.org/10.1002/hed.24276.
[34] Weledji EP. Centralization of liver cancer surgery and impact on
multidisciplinary teams working on stage IV colorectal cancer.
Onco Rev 2017;11(2):331. https://doi.org/10.4081/oncol.2017.331.
J.E.W. Walraven et al. / European Journal of Cancer 121 (2019) 85e93 93
